Search results for "Albuminuria"

showing 10 items of 154 documents

Urinary- and Plasma-Derived Exosomes Reveal a Distinct MicroRNA Signature Associated With Albuminuria in Hypertension.

2021

Urinary albumin excretion (UAE) is a marker of cardiovascular risk and renal damage in hypertension. MicroRNAs (miRNAs) packaged into exosomes function as paracrine effectors in cell communication and the kidney is not exempt. This study aimed to state an exosomal miRNA profile/signature associated to hypertension with increased UAE and the impact of profibrotic TGF-β1 (transforming growth factor β1) on exosomes miRNA release. Therefore, exosomes samples from patients with hypertension with/without UAE were isolated and characterized. Three individual and unique small RNA libraries from each subject were prepared (total plasma, urinary, and plasma-derived exosomes) for next-generation sequ…

0301 basic medicineMaleDown-Regulation030204 cardiovascular system & hematologyExosomesTransforming Growth Factor beta103 medical and health sciencesParacrine signalling0302 clinical medicinemicroRNAInternal MedicinemedicineAlbuminuriaHumansGene Regulatory NetworksKEGGCells CulturedAgedKidneybusiness.industryPodocytesReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingMiddle AgedMicrovesiclesMicroRNAs030104 developmental biologyReal-time polymerase chain reactionmedicine.anatomical_structureHypertensionAlbuminuriaCancer researchFemalemedicine.symptombusinessTransforming growth factorHypertension (Dallas, Tex. : 1979)
researchProduct

Genome-wide association study of diabetic kidney disease highlights biology involved in renal basement membrane collagen

2018

Diabetic kidney disease (DKD) is a heritable but poorly understood complication of diabetes. To identify genetic variants predisposing to DKD, we performed genome-wide association analyses in 19,406 individuals with type 1 diabetes (T1D) using a spectrum of DKD definitions basedon albuminuria and renal function. We identified 16 genome-wide significant loci. The variant with the strongest association (rs55703767) is a common missense mutation in the collagen type IV alpha 3 chain(COL4A3)gene, which encodes a major structural component of the glomerular basement membrane (GBM) implicated in heritable nephropathies. The rs55703767 minor allele (Asp326Tyr) is protective against several definit…

0303 health sciencesGlomerular basement membraneRenal function030209 endocrinology & metabolismGenome-wide association studyBiologyurologic and male genital diseasesmedicine.diseaseBioinformatics3. Good healthMinor allele frequencyPathogenesis03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureDiabetes mellitusAlbuminuriamedicineMissense mutationmedicine.symptom030304 developmental biology
researchProduct

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan : what …

2019

Albuminuria; Atrasentan; Canagliflozin Albuminuria; Atrasentan; Canagliflozina Albuminúria; Atrasentan; Canagliflozina In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) tested an already available antidiabetic drug, canagliflozin, and the Study of Diabetic Nephropathy with Atrasentan (SONAR) tested a novel molecule, the endothelin-1 receptor blocker atrasentan, both on top of renin-angiotensin system blockade. Both trials demonstrated significant nephroprot…

:compuestos heterocíclicos::compuestos heterocíclicos de 1 anillo::dioxoles::benzodioxoles::atrasentán [COMPUESTOS QUÍMICOS Y DROGAS]030232 urology & nephrologysodium-glucose cotransporter-2 (SGLT2) inhibitor:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Diabetic nephropathychemistry.chemical_compound0302 clinical medicineChronic kidney diseaseClinical endpointNefropaties diabètiques - Tractament:Other subheadings::/therapeutic use [Other subheadings]canagliflozin:Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]CanagliflozinSglt2 Inhibitors:enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas [ENFERMEDADES]Sodium-glucose cotransporter-2 (SGLT2) inhibitorNephrologyendothelinmedicine.drugmedicine.medical_specialty:hidratos de carbono::glicósidos::glucósidos::canagliflozina [COMPUESTOS QUÍMICOS Y DROGAS]UrologyRenal functionalbuminuriaEndothelinNephropathy:Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies [DISEASES]03 medical and health sciencesmedicineAlbuminuriaPirrolidina - Ús terapèutic:Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Dioxoles::Benzodioxoles::Atrasentan [CHEMICALS AND DRUGS]CanagliflozinDiabetic kidney diseaseTransplantationCreatinine:Carbohydrates::Glycosides::Glucosides::Canagliflozin [CHEMICALS AND DRUGS]atrasentan:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryAtrasentanGlucòsids - Ús terapèuticmedicine.diseasediabetic kidney diseasechemistryAtrasentanbusinesschronic kidney diseaseKidney disease
researchProduct

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, inten…

AdultBlood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismType 2 diabetesIncretinsRisk AssessmentDiabetes mellitusInternal medicinemedicineElectronic Health RecordsHumansHypoglycemic AgentsMedical prescriptionSodium-Glucose Transporter 2 InhibitorsOriginal InvestigationAgedQuality Indicators Health CareRetrospective StudiesAngiologyCardiovascular risk Humans Hypoglycemic Agents Incretins Italy Male Middle Aged Retrospective Studies Risk Assessment Sodium-Glucose Transporter 2 Inhibitors Time Factors Treatment Outcome Quality Indicators Health Care Quality of care Type 2 diabetes Adult Aged Aged 80 and over Biomarkers Blood Glucose Cardiovascular Diseases Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Heart Disease Risk Factors Female Electronic Health RecordsAged 80 and overDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMedical recordQuality of careType 2 diabetesRetrospective cohort studyMiddle AgedCardiovascular riskmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHeart Disease Risk Factorslcsh:RC666-701AlbuminuriaFemaleObservational studymedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct

Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension

1997

OBJECTIVE To analyze the relationship between insulinemia and urinary albumin excretion in a group of nonobese, young adult hypertensive patients, who had never been treated with antihypertensive drugs. PATIENTS AND METHODS Forty-nine patients who fulfilled the inclusion criteria were included. Twenty-four-hour ambulatory blood pressure monitorings, urinary albumin excretion (UAE) measurements, and an oral glucose-tolerance test measuring glucose and insulin, were performed, and left ventricular mass was measured by echocardiography. Hypertensive patients were classified as normoalbuminuric when their UAE was < 30 mg/24 h (40 patients; mean UAE 13.4 +/- 7.0 mg/24 h), and as microalbuminuric…

AdultBlood GlucoseMalemedicine.medical_specialtyAmbulatory blood pressurePhysiologymedicine.medical_treatmentUrologyBlood PressureEssential hypertensionRisk FactorsHyperinsulinismInternal medicineInternal MedicineHyperinsulinemiamedicineAlbuminuriaHumansInsulinProteinuriabusiness.industryInsulinArea under the curveGlucose Tolerance TestMiddle Agedmedicine.diseaseBlood pressureEndocrinologyCardiovascular DiseasesCase-Control StudiesHypertensionFemaleMicroalbuminuriamedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of Hypertension
researchProduct

Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study.

2003

Background: The objective of this study was to analyse the relationship of polymorphisms of the angiotensinogen (AGT) gene with the changes in microalbuminuria during 3 years of antihypertensive treatment in a group of young adults with essential hypertension. Methods: Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=23), only β-blockers (n=26), only angiotensin-converting enzyme inhibitors (ACEi) (n=57) or a combination of treatments (n=25). The office blood pressure, biochemical profile and…

AdultBlood GlucoseMalemedicine.medical_specialtyTime FactorsGenotypeAdrenergic beta-AntagonistsAngiotensinogenAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionExcretionDiabetes mellitusInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive AgentsProteinuriaPolymorphism Geneticbusiness.industrymedicine.diseaseEndocrinologyBlood pressureTreatment OutcomeACE inhibitorHypertensionMicroalbuminuriaFemaleGene polymorphismmedicine.symptombusinessmedicine.drugFollow-Up StudiesJournal of human hypertension
researchProduct

Long-Term Impact of Systolic Blood Pressure and Glycemia on the Development of Microalbuminuria in Essential Hypertension

2005

The objective was to assess the temporal impact of factors related to the development of microalbuminuria during the follow-up of young adult normoalbuminurics with high-normal blood pressure or at stage 1 of essential hypertension. Prospective follow-up was conducted on 245 normoalbuminuric hypertensive subjects (mean age 40.9 years; 134 men; blood pressure 139.7/88.6 mm Hg; body mass index 28.5 kg/m 2 ) never treated previously with antihypertensive drugs, with yearly urinary albumin excretion measurements, until the development of microalbuminuria. After enrollment, patients were placed on usual care including nonpharmacological treatment or with an antihypertensive drug regime to achie…

AdultBlood GlucoseMalemedicine.medical_specialtymedicine.drug_classBlood PressureEssential hypertensionPrehypertensionRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaHumansProspective StudiesAntihypertensive drugAntihypertensive AgentsProportional Hazards ModelsProteinuriabusiness.industryFastingmedicine.diseaseEndocrinologyBlood pressureHypertensionMultivariate AnalysisDisease ProgressionAlbuminuriaCardiologyFemaleMicroalbuminuriamedicine.symptombusinessBody mass indexFollow-Up StudiesHypertension
researchProduct

Resistive index of ophthalmic artery as an imaging biomarker of hypertension-related vascular and kidney damage

2021

Aim: Resistive index of ophthalmic artery (RI-OA) is associated with atherosclerotic diseases. The aim of this study was to evaluate the association of RI-OA and hypertension-related vascular and kidney damage. Materials and methods: Two-hundred and eighty hypertensive patients underwent evaluation of RI-OA, carotid atherosclerosis and level of 24 h albuminuria. Results: Albuminuria and carotid atherosclerosis were positively associated with RI-OA independently of other cardiovascular risk factors. Receiver-operating characteristic curve analysis allowed us to calculate a cut-off value of RI-OA &gt;0.625, which would be suspicious about the existence of atherosclerotic disease. Conclusion:…

AdultCarotid Artery DiseasesMalemedicine.medical_specialtyhypertensionSettore MED/09 - Medicina InternaImaging biomarkerClinical BiochemistryHemodynamicsDiseaseKidneyCarotid Intima-Media ThicknessalbuminuriaMicrocirculationcarotid intima-media thickneRisk FactorshemodynamicInternal medicinemedicine.arteryDrug DiscoverymedicineHumansAgedSettore MED/14 - NefrologiaKidneybusiness.industryBiochemistry (medical)Ultrasonography DopplerMiddle AgedResistive indexmedicine.anatomical_structureCardiovascular DiseasesOphthalmic arteryCardiologyAlbuminuriaFemaleKidney Diseasesophthalmic arterymedicine.symptombusinessBiomarkers
researchProduct

Impact of interval walking training managed through smart mobile devices on albuminuria and leptin/adiponectin ratio in patients with type 2 diabetes

2020

Abstract Background Interval walking training has demonstrated more pronounced positive effects on physical fitness and metabolism in type 2 diabetes (T2D), compared to continuous walking. One of the pathogenic mechanisms of T2D is associated with derangements in leptin/adiponectin axis, which might predispose affected individuals to vascular inflammation and albuminuria. The aim of this study was to investigate the effects of interval walking training delivered through smart mobile devices upon albuminuria and leptin/adiponectin ratio in patients with T2D. Methods Patients with T2D aged 35–75 were randomized into control (n = 26) and interval training (IT, n = 14) groups. Patients in IT gr…

AdultLeptinMalemedicine.medical_specialtyendocrine system diseasesPhysiologyPhysical fitnessWalkingType 2 diabetes030204 cardiovascular system & hematologylcsh:PhysiologyalbuminuriaInterval training03 medical and health sciences0302 clinical medicineleptin/adiponectin ratioPhysiology (medical)Internal medicineDiabetes mellitusinterval walkingHumansMedicineAgedlcsh:QP1-981diabetesAdiponectinbusiness.industryLeptinnutritional and metabolic diseasesOriginal Articlesmobile applicationMiddle Agedmedicine.diseaseMobile ApplicationsObesityExercise TherapyDiabetes Mellitus Type 2AlbuminuriaCardiologyOriginal ArticleFemaleAdiponectinSmartphonemedicine.symptombusinesshuman activitieshormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryPhysiological Reports
researchProduct

Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension.

2001

The objective of this study was to analyze the relationship of polymorphisms of the angiotensin II AT1 receptor gene with microalbuminuria in a group of young adults with essential hypertension. Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs, and in absence of diabetes mellitus were included. Office blood pressure (BP), 24-h ambulatory BP monitoring, urinary albumin excretion (UAE) measurements, and DNA analysis were performed. Polymorphisms of the angiotensin II AT1-receptor gene (A1166C and C573T) were studied by polymerase chain reaction and single-strand conformation polymorphism techniques. One hundred eighty-three patients, 49 (27…

AdultMaleAngiotensin receptormedicine.medical_specialtyAmbulatory blood pressureGenotypeGenetic LinkageEssential hypertensionReceptor Angiotensin Type 2Receptor Angiotensin Type 1Internal medicineInternal MedicineMedicineAlbuminuriaHumansAngiotensin II receptor type 1ProteinuriaPolymorphism GeneticReceptors Angiotensinbusiness.industryMiddle Agedmedicine.diseaseAngiotensin IIEndocrinologyHypertensionMicroalbuminuriaGene polymorphismmedicine.symptombusinessAmerican journal of hypertension
researchProduct